Abstract: A computer system includes a blockchain platform having a distributed application deployed thereon. The distributed application includes storage for storing data for smart contracts on the blockchain platform. Smart contracts communicate with and store data in the storage. An upgradeable contract object is used with this storage. A smart contract has a plurality of states and an associated sponsor. The sponsor is primarily in control of changing the states of the contract with which it is associated. The smart contract has a reference to an address registry, also on the blockchain platform, which identifies authorized potential participants. These authorized potential participants for the smart contract can elect to participant in that smart contract. When a participant elects to participate in a smart contract, the address registry is checked to verify that an individual is an authorized potential participant.

Abstract: An antigen composition with plurality of antigens from B. microti, and methods of predicting a likelihood of an individual having B. microti infection using the antigen composition as biomarkers of infections of B. microti to human are provided. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen with an average discriminatory p value of ?0.05.

Abstract: Compositions, devices, and methods are contemplated for predicting a patient's likelihood of having a disease. An antigen composition can have a plurality of autoantibody reactive antigens associated with a carrier, where at least two of the antigens have quantified and known relative autoantibody reactivities with respect to sera of a population affected by a disease. The at least two antigens can also have a known association with a disease parameter. A method can include determining autoantibody reactivity against one or more antigens or their variants in a serum sample obtained from a patient, where the autoantibody reactivity against one or more of the antigens indicates an increased likelihood of the patient having a disease.

Abstract: Compositions, devices, and methods are contemplated for predicting a patient's likelihood of having a disease. An antigen composition can have a plurality of autoantibody reactive antigens associated with a carrier, where at least two of the antigens have quantified and known relative autoantibody reactivities with respect to sera of a population affected by a disease. The at least two antigens can also have a known association with a disease parameter. A method can include determining autoantibody reactivity against one or more antigens or their variants in a serum sample obtained from a patient, where the autoantibody reactivity against one or more of the antigens indicates an increased likelihood of the patient having a disease.